Daptomycin for Infective Endocarditis

Analysis of data from a European registry revealed an overall clinical success rate of 80%, with a trend toward better results with higher doses.

In 2006, the cyclic lipopeptide antibiotic daptomycin received FDA approval for the treatment of right-sided infective endocarditis (RIE) based on the results of one of the largest infective endocarditis trials (JW Infect Dis Aug 16 2006). Since then, more patients have been treated for RIE and also (off label) for left-sided infective endocarditis (LIE).

Researchers recently published treatment results for 378 such cases that had been collected in the manufacturer-sponsored, retrospective, multicenter European Cubicin Outcomes Registry and Experience between January 2006 and June 2010. Among these patients, 259 (69%) had LIE, and 182 (48%) underwent concomitant surgery. The most frequently identified pathogens were coagulase-negative staphy…

Reviewing Author

Glück, Thomas, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Glück, Thomas, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection